PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature
- Stijn Muselaers
- Selcuk Erdem
- Riccardo Bertolo
- Alexandre Ingels
- Önder Kara
- Nicola Pavan
- Eduard Roussel
- Angela Pecoraro
- Michele Marchioni
- Umberto Carbonara
- Laura Marandino
- Daniele Amparore
- Riccardo Campi
- on behalf of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group
Publication date
March 2022
DOI Publisher
MDPI AG Journal
Journal of Clinical MedicineAbstract
Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients
Add to ORKG